Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: Lancet Infect Dis. 2022 Aug 8;23(1):e2–e21. doi: 10.1016/S1473-3099(22)00291-2

Figure 4. Historical perspective of RSV vaccine and immunoprophylaxis development over the last ten years and expected market access.

Figure 4.

Candidates that are in ongoing development (purple) or no longer in development (red) are presented at the timing of the clinical trials rounded off to full years. The darkness of the color represents the furthest development (Phase I – III) of the candidate. Candidates with multiple clinical trials are connected with full or dotted lines to show the speed of development. Live attenuated viruses by the same manufacturer are summarized in one box as development of these candidates largely overlaps. The timing of current and previous reviews are shown at the top.